Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei
Sign Up to like & getrecommendations! Published in 2018 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01739-18
Abstract: Amphotericin B deoxycholate (DAmB) is a first-line agent for the initial treatment of talaromycosis. However, little is known about the population pharmacokinetics and pharmacodynamics of DAmB for talaromycosis. ABSTRACT Amphotericin B deoxycholate (DAmB) is a… read more here.
Keywords: talaromycosis; auc mic; time; amphotericin deoxycholate ... See more keywords
AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
Sign Up to like & getrecommendations! Published in 2018 at "Trials"
DOI: 10.1186/s13063-018-3026-4
Abstract: BackgroundCryptococcal meningitis (CM) is a major cause of mortality in HIV programmes in Africa despite increasing access to antiretroviral therapy (ART). Mortality is driven in part by limited availability of amphotericin-based treatment, drug-induced toxicities of… read more here.
Keywords: trial; high dose; amphotericin deoxycholate; therapy ... See more keywords
Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
Sign Up to like & getrecommendations! Published in 2018 at "BMC Research Notes"
DOI: 10.1186/s13104-018-4036-8
Abstract: ObjectiveBased on studies in India (as there was no studies from outside India) amphotericin B deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis. However, treatment response and adverse effect to… read more here.
Keywords: treatment; amphotericin deoxycholate; visceral leishmaniasis;